Category Archives: Glucose Monitoring

MiniMed FY Q1 ’26 Earnings; Insulet Enhances O5 Algorithm and Integrates with Libre 3 Plus CGM; myLoop AID and Dexcom G7 CGM Integration Launches in EU

Three cardiometabolic-related news items have been observed: MiniMed hosted its CY Q1 ‘26 (FY Q4 ’26) earnings call (view press release; view slides); Insulet rolled out an updated O5 algorithm and expanded integration with Libre 3 Plus CGM (view press release); and CamDiab’s myLoop AID + Dexcom G7  CGM integration launched in the EU (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Preview: Where FENIX will be paying close attention and why

With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.

This content is for Read Less members only.
Already a member? Log in here

Dexcom 2026 Investor Day; “Self-Adapting” G8 CGM to Launch Late-2027

Dexcom hosted its 2026 Investor Day and provided updates across its diabetes business, including the ongoing launch of the G7 15-day, its next-gen G8 CGM, as well as a new dual glucose-potassium sensor (view slides). Following the call, Dexcom’s stock is up ~6% today. In conjunction with the Investor Day, Dexcom also announced updates to its governance structure, including the planned addition of two new independent board members (view press release). Below are highlights and insights from the investor event.

This content is for Read Less members only.
Already a member? Log in here